RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes

Inclusion Criteria:

* Age 18 years or older at enrollment.
* Diagnosis of type 1 diabetes mellitus, type 2 diabetes mellitus, or gestational diabetes mellitus.
* Gestational age of at least 12 weeks.
* Singleton pregnancy.
* Willing to wear one sensor on each upper arm simultaneously.
* Able to follow study-site instructions and complete all protocol-required tasks.
* Willing and able to provide signed written informed consent.
* Able to speak, read, and write German or Mandarin.

Exclusion Criteria:

* Known allergy to, or inability to tolerate, medical-grade adhesive tape.
* Extensive unresolved skin changes or diseases at sensor wear sites that prevent sensor placement, including extensive psoriasis, recent burns or severe sunburn, extensive eczema, scarring, tattoos, or dermatitis herpetiformis.
* Hematocrit below 30%.
* Hemoglobin below 11.0 g/dL in the first or third trimester, or below 10.5 g/dL in the second trimester, at screening.
* Body weight below 55 kg at screening.
* Inadequate venous access in the arms.
* Stage 3 or higher renal insufficiency (eGFR below 60 mL/min/1.73 m²), current dialysis, or planned dialysis during sensor wear.
* Prescribed medication for preterm labor or high-risk complications in the current pregnancy, including:
* Use of tocolytics, such as atosiban, nifedipine, terbutaline, ritodrine, or magnesium sulfate.
* Use of progesterone for preterm birth prevention, including 17-hydroxyprogesterone caproate or vaginal progesterone.
* Placenta previa, placental abruption, preterm premature rupture of membranes, cervical insufficiency or short cervix, preeclampsia/eclampsia, or fetal growth restriction with abnormal Doppler flow.
* History of preterm birth before 34 weeks, or any condition that places the participant or fetus at undue risk in the Investigator's judgment.
* Implanted pacemaker or implantable cardioverter-defibrillator.
* Preeclampsia or eclampsia, including HELLP syndrome; severe cardiovascular disease; malignancy; severe liver dysfunction, including intrahepatic cholestasis of pregnancy or acute hepatic steatosis; known coagulation disorders; uncontrolled thyroid dysfunction; severe neurological disorders; or severe psychiatric disorders.
* Critical illness or a medical or psychiatric history that, in the Investigator's opinion, poses a participation risk or interferes with study compliance.
* Any condition that interferes with participation or poses excessive risk to study staff, including active illegal substance use or an active psychiatric disorder.
* Infectious disease, including AIDS, HIV, hepatitis B, or hepatitis C infection.
* A condition requiring or likely to require MRI, CT, positron emission tomography, angiography, X-ray, phototherapy, or diathermy during the study.
* Participation in another clinical trial within 2 weeks before screening, or planned participation in another clinical trial during this study.
* Any other reason making participation unsuitable in the Investigator's judgment, including acute febrile infection or acute exacerbation of a chronic disease.
* Severe hypoglycemia associated with seizure or loss of consciousness within 6 months before screening.
* Hypoglycemia unawareness within 6 months before screening, defined as inability to perceive or recognize symptoms of low blood glucose.
* Inability to independently read the product Instructions for Use or required user training materials.